Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06582745 · ClinicalTrials.gov registry record · Phase 2
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by Cook Children's Health Care System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06582745: Recruiting Phase 2 study of Langerhans Cell Histiocytosis, sponsored by Cook Children's Health Care System.
NCT06582745 is a Phase 2 study of Langerhans Cell Histiocytosis that is actively recruiting participants, run by Cook Children's Health Care System. The registered enrollment target is 75 participants, below the 1,130-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06582745, a Phase 2 study of Langerhans Cell Histiocytosis, is actively recruiting participants, sponsored by Cook Children's Health Care System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric patients.
Primary Outcome
TTP defined for each participant as the period of time from start of treatment to the manifestation of objective progression, but excluding occurrences of death.
Conditions Studied
Interventions
- DRUG Trametinib
Study Locations (1)
Texas
- Cook Children's Health Care System - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2039-12 |
| Phase | Phase 2 |
What NCT06582745 shows while recruiting
NCT06582745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 1,130-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 1 intervention - of which Trametinib is the first listed.
NCT06582745 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06582745 about?
NCT06582745 is a clinical study titled "Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib". The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric patients.
What is the current status of trial NCT06582745?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2024-06-24. Estimated completion is 2039-12.
What conditions does trial NCT06582745 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT06582745?
The interventions under investigation include: Trametinib (DRUG).
Who is sponsoring clinical trial NCT06582745?
This trial is sponsored by Cook Children's Health Care System, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06582745 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06582745's enrollment target sits among peer trials
75 6th of 8 higher than 3 of 8 other Langerhans Cell Histiocytosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Langerhans Cell Histiocytosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
COMPLETED · Phase 2
-
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI